Predictive impact of allele-matching and EBMT risk score for outcome after T-cell depleted unrelated donor transplantation in poor-risk acute leukemia and myelodysplasia

被引:14
作者
Lodewyck, T.
Oudshoorn, M. [2 ,3 ,4 ]
van der Holt, B. [5 ]
Petersen, E. [6 ]
Spierings, E. [7 ]
von dem Borne, P. A. [8 ]
Schattenberg, A. [9 ]
Allebes, W. [10 ]
Groenendijk-Sijnke, M. [11 ]
Duinhouwer, L.
Willemze, R. [8 ]
Lowenberg, B.
Verdonck, L. F. [12 ]
Meijer, E.
Cornelissen, J. J. [1 ]
机构
[1] Erasmus MC, Dept Hematol, Daniel den Hoed Canc Clin DDHK, NL-3075 EA Rotterdam, Netherlands
[2] Leiden Univ Med Ctr, Blood Transfus Serv, Leiden, Netherlands
[3] Leiden Univ Med Ctr, Dept Immunohematol, Leiden, Netherlands
[4] Europdonor Fdn, Leiden, Netherlands
[5] Erasmus Univ Med Ctr Daniel den Hoed, Trials & Stat HOVON Data Ctr, Rotterdam, Netherlands
[6] Univ Med Ctr Utrecht, Dept Hematol, Utrecht, Netherlands
[7] Univ Med Ctr Utrecht, Dept Immunol, Utrecht, Netherlands
[8] Leiden Univ Med Ctr, Dept Hematol, Leiden, Netherlands
[9] Radboud Univ Nijmegen Med Ctr, Dept Hematol, Nijmegen, Netherlands
[10] Radboud Univ Nijmegen Med Ctr, Lab Med Immunol, Nijmegen, Netherlands
[11] Erasmus MC, HOVON Data Ctr, NL-3075 EA Rotterdam, Netherlands
[12] Isala Clin, Dept Internal Med, Zwolle, Netherlands
关键词
acute leukemia; allele-matching; unrelated donor transplantation; ACUTE MYELOID-LEUKEMIA; 1ST COMPLETE REMISSION; BONE-MARROW-TRANSPLANTATION; HLA CLASS-I; ACUTE LYMPHOBLASTIC-LEUKEMIA; COMORBIDITY INDEX; ALLOGENEIC TRANSPLANTATION; COMPARABLE SURVIVAL; CHRONIC GRAFT; ADULTS;
D O I
10.1038/leu.2011.123
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Many parameters predict for outcome after unrelated donor (URD) allogeneic hematopoietic stem cell transplantation (alloSCT). High-resolution HLA-matching significantly impacts outcome and also the European Group of Blood and Marrow Transplantation (EBMT) risk score, based on patient age, disease stage, donor type, time from diagnosis to SCT and gender combination, may predict for non-relapse mortality and overall survival (OS). We evaluated the individual and combined effects of allele-matching and the EBMT risk score in 327 patients with poor-risk acute leukemia or myelodysplasia, who received a T-cell depleted URD alloSCT. Matching for HLA-A, -B, -C and -DRB1 alleles (8/8 match) was associated with a 5-year OS of 40% compared with 30% for mismatched (<= 7/8) pairs (P = 0.02). Patients with EBMT risk scores of 1-2, 3, 4 and 5-7 had 5-year OS estimates of 53, 43, 30 and 20%, respectively (P<0.001). The favorable prognostic impact of an 8/8 donor was most pronounced if the EBMT risk score was low (1-2). Five-year OS was 74 +/- 8% vs 39 +/- 11% for fully matched patients with a low-risk EBMT score as compared with EBMT low-risk patients with <= 7/8 donors. These data underscore the importance of incorporating both the EBMT risk score and the degree of high-resolution HLA-matching in the risk assessment prior to URD alloSCT. Leukemia (2011) 25, 1548-1554; doi:10.1038/leu.2011.123; published online 24 May 2011
引用
收藏
页码:1548 / 1554
页数:7
相关论文
共 42 条
[1]   Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML) [J].
Appelbaum, Frederick R. .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2008, 21 (01) :85-92
[2]   Hematopoietic cell transplantation from unrelated donors for treatment of patients with acute myeloid leukemia in first complete remission [J].
Appelbaum, Frederick R. .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2007, 20 (01) :67-75
[3]   Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission [J].
Basara, N. ;
Schulze, A. ;
Wedding, U. ;
Mohren, M. ;
Gerhardt, A. ;
Junghanss, C. ;
Peter, N. ;
Doelken, G. ;
Becker, C. ;
Heyn, S. ;
Kliem, C. ;
Lange, T. ;
Krahl, R. ;
Poenisch, W. ;
Fricke, H-J ;
Sayer, H. G. ;
Al-Ali, H. ;
Kamprad, F. ;
Niederwieser, D. .
LEUKEMIA, 2009, 23 (04) :635-640
[4]  
CLIFT R, 1989, BONE MARROW TRANSPL, V4, P445
[5]   A scheme for defining cause of death and its application in the T cell depletion trial [J].
Copelan, Edward ;
Casper, James T. ;
Carter, Shelly L. ;
van Burik, Jo-Anne H. ;
Hurd, David ;
Mendizabal, Adam M. ;
Wagner, John E. ;
Yanovich, Saul ;
Kernan, Nancy A. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (12) :1469-1476
[6]   Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? [J].
Cornelissen, Jan J. ;
van Putten, Wim L. J. ;
Verdonck, Leo F. ;
Theobald, Matthias ;
Jacky, Emanuel ;
Daenen, Simon M. G. ;
Kooy, Marinus van Marwijk ;
Wijermans, Pierre ;
Schouten, Harry ;
Huijgens, Peter C. ;
van der Lelie, Hans ;
Fey, Martin ;
Ferrant, Augustin ;
Maertens, Johan ;
Gratwohl, Alois ;
Lowenberg, Bob .
BLOOD, 2007, 109 (09) :3658-3666
[7]   HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry [J].
Crocchiolo, R. ;
Ciceri, F. ;
Fleischhauer, K. ;
Oneto, R. ;
Bruno, B. ;
Pollichieni, S. ;
Sacchi, N. ;
Sormani, M. P. ;
Fanin, R. ;
Bandini, G. ;
Bonifazi, F. ;
Bosi, A. ;
Rambaldi, A. ;
Alessandrino, P. E. ;
Falda, M. ;
Bacigalupo, A. .
BONE MARROW TRANSPLANTATION, 2009, 44 (09) :571-577
[8]   The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation [J].
Farina, L. ;
Bruno, B. ;
Patriarca, F. ;
Spina, F. ;
Sorasio, R. ;
Morelli, M. ;
Fanin, R. ;
Boccadoro, M. ;
Corradini, P. .
LEUKEMIA, 2009, 23 (06) :1131-1138
[9]   Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome [J].
Flomenberg, N ;
Baxter-Lowe, LA ;
Confer, D ;
Fernandez-Vina, M ;
Filipovich, A ;
Horowitz, M ;
Hurley, C ;
Kollman, C ;
Anasetti, C ;
Noreen, H ;
Begovich, A ;
Hildebrand, W ;
Petersdorf, E ;
Schmeckpeper, B ;
Setterholm, M ;
Trachtenberg, E ;
Williams, T ;
Yunis, E ;
Weisdorf, D .
BLOOD, 2004, 104 (07) :1923-1930
[10]   In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) [J].
Goldstone, Anthony H. ;
Richards, Susan M. ;
Lazarus, Hillard M. ;
Tallman, Martin S. ;
Buck, Georgina ;
Fielding, Adele K. ;
Burnett, Alan K. ;
Chopra, Raj ;
Wiernik, Peter H. ;
Foroni, Letizia ;
Paietta, Elisabeth ;
Litzow, Mark R. ;
Marks, David I. ;
Durrant, Jill ;
McMillan, Andrew ;
Franklin, Ian M. ;
Luger, Selina ;
Ciobanu, Niculae ;
Rowe, Jacob M. .
BLOOD, 2008, 111 (04) :1827-1833